Study evaluates Pfizer-BioNTech vaccine effectiveness during the Delta and Omicron periods in children 5-18 years of age

NewsDesk @bactiman63 Results of a new multicenter study published in the New England Journal of Medicine found that vaccination with a primary series of the Pfizer-BioNTech mRNA COVID-19 vaccine reduced the risk of COVID-19-associated hospitalizations in children ages 5-11 years by two-thirds during the Omicron period. Among adolescents ages 12-18 years who were vaccinated with a primary series [...]

The post Study evaluates Pfizer-BioNTech vaccine effectiveness during the Delta and Omicron periods in children 5-18 years of age appeared first on Outbreak News Today.